ArticleVaccines2022
The Association between Risk Perception and Hesitancy toward the Booster Dose of COVID-19 Vaccine among People Aged 60 Years and Older in China.
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review.Human vaccines & immunotherapeutics · 2023Pooled it
- Outcomes of Elderly Patients Hospitalized with the SARS-CoV-2 Omicron B.1.1.529 Variant: A Systematic Review.International journal of environmental research and public health · 2023Pooled it
- Perceived risk and time costs as correlates of hepatitis vaccine hesitancy among Chinese university students: A ten‑university cross‑sectional study.Human vaccines & immunotherapeutics · 2026Article
- COVID-19 pandemic and vaccine hesitancy in a Brazilian state capital.Scientific reports · 2026Article
- Delay discounting predicts COVID-19 vaccine booster willingness.Cognitive research: principles and implications · 2025Article
- Global disparities in COVID-19 vaccine booster dose (VBD) acceptance and hesitancy: An updated narrative review.Vaccine: X · 2024Review
- COVID-19 Vaccine Booster Hesitancy among the Elderly in Malaysian Residential Care Homes: A Cross-Sectional Study in Klang Valley.Vaccines · 2024Article
- Uptake and correlates of influenza vaccine among older adults residing in rural regions of south China: a cross-sectional study.Frontiers in public health · 2024Article
- Willingness to receive the second booster of COVID-19 vaccine among older adults with cancer: a stratified analysis in four provinces of China.Frontiers in public health · 2024Article
- Is vaccine hesitancy related to mental health after the adjustment of the zero-COVID-19 strategy in the elderly? A mediation analysis in China.Human vaccines & immunotherapeutics · 2023Article
- Article
- Assessing the acceptability of COVID-19 vaccine and its booster dose.Immunity, inflammation and disease · 2023Article
- COVID-19 Booster Dose Coverage and Hesitancy among Older Adults in an Urban Slum and Resettlement Colony in Delhi, India.Vaccines · 2023Article
- Factors Affecting the Public Intention to Repeat the COVID-19 Vaccination: Implications for Vaccine Communication.Healthcare (Basel, Switzerland) · 2023Article
- Analysis of Differences in User Groups and Post Sentiment of COVID-19 Vaccine Hesitators in Chinese Social-Media Platforms.Healthcare (Basel, Switzerland) · 2023Article
- Dark Triad and COVID-19 vaccine hesitancy: the role of conspiracy beliefs and risk perception.Current psychology (New Brunswick, N.J.) · 2023Article
- Article
- COVID-19 Vaccination Coverage among 42,565 Adults Amid the Spread of Omicron Variant in Beijing, China.Vaccines · 2023Article
- Why Some People Are Hesitant to Receive COVID-19 Boosters: A Systematic Review.Tropical medicine and infectious disease · 2023Review
- Policy Endorsement and Booster Shot: Exploring Politicized Determinants for Acceptance of a Third Dose of COVID-19 Vaccine in China.Vaccines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundGiven the prevalence of the omicron variant and decreased immunity provided by vaccines, it is imperative to enhance resistance to COVID-19 in the old population. We planned to explore the hesitancy rate toward the booster dose of the COVID-19 vaccine and the association between risk perception and the abovementioned rate among people aged 60 and older.
methodsThis national cross-sectional study was conducted in mainland China from 25 May to 8 June 2022, targeting people who were 60 years old or above. Four dimensions were extracted from the Health Belief Model (HBM) to assess participants' perceived risk levels, including perceived susceptibility, perceived severity, perceived barriers, and perceived benefit. An independent Chi-square test was used to compare the vaccine hesitancy rates among different groups stratified by characteristics. Univariable and multivariable logistic regression models were performed to explore the associations between risk perception and hesitancy rate.
resultsOf 3321 participants, 17.2% (95% CI: 15.9-18.5%) were hesitant about booster shots of COVID-19 vaccines. Believing that they were ineligible for vaccination due to certain illnesses (38.3%), concern about vaccine safety (32.0%), believing the booster shots were unnecessary (33.1%), and their limitation on movements (28.0%) were the main reasons for vaccine hesitation. Adjusted by all the selected covariates, people with low perception level of susceptibility (aOR = 1.39, 95% CI: 1.00-1.92) and benefit (low: aOR = 3.31, 95% CI: 2.01-5.45; moderate: aOR = 2.23, 95% CI: 1.75-2.85) were less likely to receiving the booster dose, and the same results were found in people with higher perceived barriers (moderate: aOR = 2.67, 95% CI: 2.13-3.35; high: aOR = 2.04, 95% CI: 1.14-3.67). Our estimates were stable in all four models.
conclusionsIn total, 17.2% of the people aged 60 years and older in China were hesitant about booster dose of COVID-19 vaccines, and it was closely associated with a lower level of perceived susceptibility and benefit, as well as a higher level of perceived barriers. Concerns about contraindications, vaccine safety, and limited movements were the main reasons for vaccine hesitancy. Targeted public health measure is a priority to improve the understanding of the elderly on their own susceptibility and vulnerability and clear the obstacles to vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.